Abstracts tagged "Mouse Models, Other"

Abstract Number: 2462 • ACR Convergence 2024
A Potent Inhibitor of PAI-1, MDI-2517, Mitigates Disease Severity in Preclinical Models of Systemic Sclerosis
Enming Su¹, Pei-Suen Tsou¹, Mark Warnock², Natalya Subbotina¹, Kris Mann¹, Sirapa Vichaikul¹, Xianying Xing¹, Enze Xing¹, Olesya Plazyo¹, Rachael Wasikowski¹, Lam C. Tsoi³, Mark Weinberg⁴, Cory D. Emal⁵, Dinesh Khanna¹, John Varga¹, Thomas H. Sisson¹, Johann Gudjonsson¹ and Daniel Lawrence², ¹University of Michigan, Ann Arbor, MI, ²Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, ³Michigan, Dept. of Dermatology, Ann Arbor, MI, ⁴MDI, Ann Arbor, MI, ⁵EMU, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is a complex and heterogeneous condition characterized by progressive fibrosis in multiple organs. Currently, there is no known cure for SSc,…
Abstract Number: 0014 • ACR Convergence 2024
Phenotypic Validation of Humanized IgA1 and CD89 Transgenic Mice as a Model for IgA Nephropathy-Like Autoimmune Disease
Kaiyuan Zi and Juan Liang, GemPharmatech, San Diego
Background/Purpose: The etiology of IgA nephropathy (IgAN) remains only partly understood, but the presence of IgA antibodies together with the myeloid IgA-receptor FcαRI/CD89 complexes in…
Abstract Number: 0019 • ACR Convergence 2024
A Novel Product Candidate (CPTX2309) for In Vivo mRNA Engineering of Anti-CD19 CAR T Cells Utilizing Novel CD8-Targeted Lipid Nanoparticles
Theresa Hunter¹, Ferran Soldevila¹, Yan Zhang¹, Brittany Ross¹, Daiki Matsuda¹, Yanjie Bao¹, John Li¹, Michelle Nguyen¹, Matthew Butcher¹, MIchael Pica¹, Claudia Fernandez¹, James Vestal¹, Goutam Mondal¹, Yi Kuo¹, Jeffrey Chen¹, Josephine Nguyen², Young Yoon Choi², Diana Galvan¹, Duy Nguyen¹, Donald Jhung², Stuart Sievers¹, Steven Tanis¹, Cory Bentley², Michael Rosenzweig¹, Priya Karmali¹, Adrian Bot¹, Haig Aghajanian¹ and Gregor Adams¹, ¹Capstan Therapeutics, San Diego, CA, ²Capstan Therapeutics, San Diego
Background/Purpose: Ex vivo chimeric antigen receptor (CAR) T cell therapies have revolutionized cancer treatment and are demonstrating clinical efficacy in various autoimmune disease indications. Despite…
Abstract Number: 0025 • ACR Convergence 2024
Vagus Nerve Stimulation: A Promising Approach to Alleviate Pain and Systemic Inflammation in Slow and Rapid Models of Osteoarthritis
Shivmurat Yadav¹, Timothy Griffin², Matlock Jeffries², Stavros Stavrakis³ and Mary Beth Humphrey⁴, ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³University of Oklahoma, College of Mediicine, Oklahoma City, OK, ⁴University of Oklahoma College of Medicine, Oklahoma City, OK
Background/Purpose: Osteoarthritis (OA) causes joint pain, stiffness, swelling, and functional impairment. Pain signals reach the brain, influencing inflammatory and immune responses through the parasympathetic efferent…
Abstract Number: 0803 • ACR Convergence 2023
IL10 Inhibits Toll-like Receptor-9-induced T Cell Receptor-mediated T Cell Activation in Macrophage Activation Syndrome
Matthew Eremita¹, Omar Geier², Joyce Hui-Yuen¹ and Matthew Taylor³, ¹Division of Pediatric Rheumatology, Cohen Children's Medical Center, Lake Success, NY, ²Sepsis Research Laboratory, Feinstein Institutes for Medical Research, Manhasset, NY, ³Division of Pediatric Critical Care, Cohen Children's Medical Center, Manhasset, NY
Background/Purpose: Macrophage activation syndrome (MAS) is a potentially fatal complication of systemic juvenile idiopathic arthritis (sJIA). Gene expression pathway analyses have identified altered Toll-like receptor…
Abstract Number: 0870 • ACR Convergence 2023
Targeting Peroxisome Proliferator-Activated Receptor α Is a Disease-Modifying Therapy for Osteoarthritis
Uxía nogueira Recalde¹, Patricia Díaz rodríguez², Francisco J. Blanco³, Eduardo Dominguez Medina⁴ and Beatriz Carames⁵, ¹Unidad de Biología del Cartílago, Grupo de Reumatología, Instituto de Investigación Biomedica de A Coruña (iNIBIC), A Coruña, Spain, ²Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Pharmacy School, Santiago de Compostela, Spain, ³Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ⁴Center for Research in Molecular Medicine and Chronic Diseases, Santiago de Compostela, Spain, ⁵Unidad de Biología del Cartílago, Grupo de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain
Background/Purpose: Disease-modifying therapeutic agents to prevent progression of Osteoarthritis (OA) are an urgent clinical need. Targeting senescence and autophagy in chondrocytes with small molecules is…
Abstract Number: 0880 • ACR Convergence 2023
CD14 Inhibition as a Potential Therapeutic in Post Traumatic OA
Kevin Burt¹, Vu Nguyen¹, Lance Murphy², De'Broski Herbert¹, Robert Mauck¹ and Carla Scanzello³, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ³Translational Musculoskeletal Research Center, Corp. Michael J Crescenz VA Medical Center,4Division of Rheumatology, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA
Background/Purpose: Osteoarthritis (OA) is the most common joint disorder, and growing evidence has identified inflammation to be a major driver of disease progression. During disease,…
Abstract Number: 1591 • ACR Convergence 2023
Complement Factor D/Adipsin Knockout Mice Demonstrate Disparate Pain and Structural Damage Phenotypes in Obesity-induced Post Traumatic Osteoarthritis
Kelsey Collins¹, Kristin Lenz², Arin Oestreich², Luke Springer², Antonina Akk², Huimin Yan², Xiaobo Wu², John Atkinson³, Christine Pham⁴ and Farshid Guilak⁴, ¹University of California San Francisco, San Francisco, CA, ²Washington University in St. Louis, St. Louis, MO, ³Washington University School of Medicine, St. Louis, MO, ⁴Washington University, St. Louis, MO
Background/Purpose: Osteoarthritis (OA) is the leading cause of musculoskeletal pain, which is a primary driver of care-seeking behavior. There is lack of mechanistic information detailing…
Abstract Number: 1730 • ACR Convergence 2023
Gut Microbiota Dysbiosis Impact Autonomic Function in Rheumatoid Arthritis Patients
Rachel AUDO¹, Jérome Thireau², Louis Rauzier³, Marie Barozet¹, JACQUES MOREL⁴, Patrice Bideaux³, alain Lacampagne² and Claire Daien⁵, ¹CHU Montpellier, Montpellier, France, ²PhyMedExp INSERM U1046, Montpellier, France, ³PhyMedExp U1046, Montpellier, France, ⁴Protocole thérapeutique immuno-rhumatologie, Montpellier, France, ⁵University Hospital, Montpellier, France
Background/Purpose: Rheumatoid arthritis (RA) is associated with a high risk of cardiovascular (CV) risks, including accelerated atherosclerosis, left ventricular hypertrophy and decreased heart rate variability…
Abstract Number: 1776 • ACR Convergence 2023
Macrophage Migration Inhibitory Factor May Help Maintain Tight Junctions in the Gut by Enhancing Occludin Expression
Shaghayegh Foroozan¹ and Nigil Haroon², ¹University Health Network/University of Toronto, Toronto, ON, Canada, ²University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Medicine/Rheumatology, Toronto, ON, Canada
Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory disease with multifactorial origins, primarily affecting the musculoskeletal system. Gut inflammation is seen in the majority of…
Abstract Number: 1784 • ACR Convergence 2023
Dendritic Cell-specific TNFR2 Depletion Reduces Psoriatic Arthritis-like Disease in a Mouse Model
Raminderjit Kaur¹, M. Elaine Husni², Unnikrishnan Chandrasekharan³ and Roberta Brambilla⁴, ¹Cleveland Clinic, Cleveland,, OH, ²Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, ³Cleveland Clinic, Cleveland, OH, ⁴University of Miami Miller School of Medicine, Miami,, FL
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, progressive autoimmune condition that affects both the skin and joints. It is characterized by increased levels of the…
Abstract Number: 1786 • ACR Convergence 2023
Newly Identified Gut Commensal Clostridium Fessum AM100 for Treating Ankylosing Spondylitis
Lu Bai¹, Chengkai Zhu¹, Yihong Xu², Kunhai Tang¹, Dachun Zhuo¹, Qing Zhang¹, Chengchun Geng¹, Weidong Xu², Hao Wu¹, Xingdong Chen¹ and Jiucun Wang¹, ¹Fudan University, Shanghai, China, ²Changhai Hospital, Shanghai, China
Background/Purpose: Ankylosing spondylitis (AS) is an inflammatory disease of the spinal joints leading to progressive loss of spinal mobility and chronic pain. Gutdysbiosis has been…
Abstract Number: 1788 • ACR Convergence 2023
The Emerging Mechanism of TNF&IL-17A/WNT5a/ROR2 Axis in Pathological Bone Formation of Ankylosing Spondylitis
Sungsin Jo¹, Seung Hoon Lee¹, Chanhyeok Jeon¹, Sung Hoon Choi², Ye-Soo Park³ and Tae-Hwan Kim⁴, ¹Hanyang University Institute for Rheumatology Research, Seoul, South Korea, ²Hanyang University Seoul Hospital, Seoul, South Korea, ³Hanyang University College of Medicine, Guri, South Korea, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Enthesitis is one of the most distinctive features and signs of ectopic bone formation in ankylosing spondylitis (AS). The Wnt/β-catenin pathway and Th17 cells…
Abstract Number: 1789 • ACR Convergence 2023
Microtrauma Exacerbates Arthritis and Enthesitis in Curdlan-administered SKG Mice by Inducing FGF16 Expresssion
Seung Hoon Lee¹, Chanhyeok Jeon¹, Sungsin Jo¹ and Tae-Hwan Kim², ¹Hanyang University Institute for Rheumatology Research, Seoul, South Korea, ²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Microtrauma might be considered a crucial of various environmental factors in AS, but there is still unknown whether microtrauma has a direct/indirect role in…
Abstract Number: 1793 • ACR Convergence 2023
Goblet Cell Specific Anti-Apoptotic Role of Interleukin-24 in Spondyloarthritis-Associated Ileitis
Amy Cameron¹, Rabina Giri², Jakob Begun², Timothy Wells¹, Ranjeny Thomas³ and Anne-Sophie Bergot¹, ¹Frazer Institute, The University of Queensland, Woolloongabba, Australia, ²Mater Research Institute-UQ, Woolloongabba, Australia, ³Frazer Institute, The University of Queensland, Brisbane, Australia
Background/Purpose: The loss of intestinal barrier integrity is a key contributor to gut inflammation, however the mechanism behind this dysregulation is not well understood. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].